A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; Etoposide; Rituximab; Topotecan; Vincristine
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 20 Nov 2018 Planned number of patients changed from 135 to 165.
- 20 Nov 2018 Planned primary completion date changed from 31 Dec 2021 to 25 Apr 2021.
- 29 May 2018 Planned primary completion date changed from 25 Apr 2021 to 31 Dec 2021.